
![]() |
|||||||||||||
WJPR Citation Report
|
| All | Since 2021 | |
| Citation | 9186 | 4781 |
| h-index | 32 | 25 |
| i10-index | 256 | 108 |
REGULATORY REQUIREMENTS AND GENERIC DRUG DOSSIER COMPILATION FOR ORAL DISINTEGRATING TABLETS IN THE USA
Y. Manjula, Sravani, B. Chandra Shekhar Reddy*
Abstract Orally disintegrating tablets (ODTs) are solid oral dosage forms that disintegrate rapidly in the mouth and offer an alternative to conventional tablets that require water for administration. They are especially useful for patients who have difficulty swallowing, including children and older adults. Developing generic ODTs requires thorough evaluation of formulation, manufacturing, quality control, dissolution, stability, taste masking, and bioequivalence. In the United States, eligible generic ODTs are generally submitted through the Abbreviated New Drug Application (ANDA) pathway. The regulatory dossier contains administrative, quality, nonclinical, and clinical or bioequivalence information organized within the Common Technical Document (CTD) framework. This review discusses the regulatory pathway, dossier compilation, quality and chemistry, manufacturing and controls (CMC), ODTspecific formulation considerations, bioequivalence, BCS-based biowaivers, and recent developments in US regulatory requirements. Particular emphasis is placed on the assimilation of pharmaceutical development data into a complete generic ODT dossier for submission to the US Food and Drug Administration (FDA). Keywords: Orally disintegrating tablets; generic drugs; ANDA; US FDA; regulatory dossier; CTD; CMC; bioequivalence; BCS biowaiver. [Full Text Article] [Download Certificate] |
